Join
Live feed
·
PRReleasevia Quantisnow
Dyne Therapeutics Inc. logo

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

ByQuantisnow·Wall Street's wire, on your screen.
DYN· Dyne Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DYN (Dyne Therapeutics Inc.) and more on Quantisnow.